Nathan Farrokhian, Jeff Maltas, Mina Dinh, Arda Durmaz, Patrick Ellsworth, Masahiro Hitomi, Erin McClure, Andriy Marusyk, Artem Kaznatcheev, Jacob G ScottRead the preprint
Figure 1To understand this outcome, it is important to realize that tumor subclones do not live or reproduce in isolation. Genomic instability inherent to the mechanism of oncogenesis promotes intratumoral heterogeneity. With this diverse cellular population comes a diverse range of intercellular interactions. These dynamics are thought to drive resulting equilibrium amongst the constituents. As such mathematical modeling of these interactions with game theoretical methodology has gained in popularity. Dynamic therapeutic protocols using models of this type have already made their way into the clinic with promising results (Figure 2). Specifically, a clinical trial in castration resistant prostate cancer utilized this framework to develop an adaptive protocol that not only decreased cumulative drug dose, but more importantly significantly lengthened time to progression in this population.
Figure 2While these successes highlight the potential of these models to revolutionize chemotherapeutic protocols, they often rely heavily on biological conjecture and intuition to derive model parameters. These parameters drive the resulting evolutionary equilibria and even small changes in their relative values can result in completely different ecological endpoints (Figure 3).
Figure 3To bridge this gap between theory and clinical application, Kaznatcheev et al. developed a method to measure and parametrize these games and their evolutionary consequences in the in vitro setting (Figure 4).
Figure 4In our recent preprint, we utilized this methodology to show that frequency dependent interactions ameliorate the fitness cost of gefitinib resistance in an in vitro EGFR+ lung cancer population, which leads to a potential safe harbor for small resistant sub-populations (Figure 5).
Figure 5As expected, introduction of gefitinib reverses these interactions such that the resistant population promotes more rapid extinction of the non-resistant cells. Most importantly, at clinically relevant doses, this interaction outweighs the effect of the drug itself (Figure 6).
Figure 6Using these in vitro derived parameters, we generated in silico models to investigate the implication of these frequency dependent interactions (Figure 7). As expected, higher doses of gefitinib resulted in larger initial decreases in tumor volume. This was largely due to accelerated extinction of the parental cells driven by interaction with the resistant cells. Importantly, this rapid extinction allowed for more rapid expansion of the resistant cells. As a result, this rapid reduction in tumor volume was met with a similarly rapid rebound in disease burden. Comparatively, while lower doses of gefitinib resulted in more modest initial decreases in tumor volume, maintenance of underlying tumor heterogeneity promoted a more durable response (Figure 7E)..
Figure 7In other words, exploitation of the growth exclusion that results from interspecific competition allowed for improved chronic control of the tumor. This was largely dictated by the slower extinction of the parental population, whose presence continued to limit outgrowth of the resistant population - a feature that persisted across all models tested. As such, using monoculture estimates to predict shifts in population equilibria can be largely inaccurate and must be measured prior to the development of adaptive therapeutic protocols that rely on maintenance of underlying tumor heterogeneity.
© 2023 - The Mathematical Oncology Blog